Oncology
Oncology
Welcome to Johnson & Johnson Medical Cloud — Oncology
Johnson & Johnson Medical Cloud Oncology is a platform that provides you as a healthcare professional with relevant and useful information in the field of uro-oncology, and more specifically with regard to prostate cancer.
This professional platform gives you easy access to our online and offline medical education programs, which include the most recent updates from the major conferences within your field (ASCO, ASCO-GU, ESMO, EAU, APCCC).
In addition, you can access our clinical trials and the Johnson & Johnson oncology portfolio from this resource with ease — including all supporting scientific studies and useful materials for your patients.
Portfolio
Consult practical information about Johnson & Johnson Oncology, find out about our registration studies, current clinical studies and more.
Visit our medical education platform
Oncology Medical Education (OME) offers education and is a platform to exchange insights in the field of oncology.
View our complete calendar
Johnson & Johnson follows medical news closely and compiles a handy calendar for you with the most important events in your field.
Check out our supporting materials
Download or order materials to support the treatment of your patients.
News
European market authorization for Erleada (Apalutamide)
On January 27, 2020, the European Commission (EMA) announced approval of ERLEADA for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with ADT. Until now, ERLEADA was only registered for adult men with non-metastatic castration-resistant prostate cancer (nmCRPC) with a high risk of metastatic disease.
Erleada (Apalutamide) now reimbursed in Luxembourg
From July 2020, ERLEADA® will be reimbursed in Luxembourg (national no. 0885824) in adult men for the treatment of:
- non-metastatic castration-resistant prostate cancer (nmCRPC) with a high risk of developing metastatic disease
- metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT)
Erleada (Apalutamide) now reimbursed in Belgium
From September 2021, ERLEADA will be reimbursed in Belgium in adult men for the treatment of:
- non-metastatic castration-resistant prostate cancer (nmCRPC) with a high risk of developing metastatic disease in combination with androgen deprivation therapy (ADT)
- metastatic hormone-sensitive prostate cancer (mHSPC) in combination with ADT
Resources
Online library
In the online library you can check out over 800 oncology books digitally.
Treatment guidelines
Consult the selection of guidelines with recommendations for the treatment of prostate cancer.
Contact us, we're happy to help
Do you have a question for us or did you not find what you were looking for? Let us know and one of our Johnson & Johnson's specialists will contact you as soon as possible.
Discover our products
Discover here the Johnson & Johnson's portfolio and product SmPC's.
Look at 3D clinical images
On this page you will find interactive 3D animations of the human anatomy and various syndromes. This allows you to zoom in on the anatomy, tissue structures, disease mechanisms and the course of the disease.
*PSA: Prostate-Specific Antigen
CP-231367 June 2023
